(4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid

Base Information Edit

Chemical Name:(4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid
CAS No.:475085-57-5
Molecular Formula:C25H29N3O3
Molecular Weight:419.524
Hs Code.:
UNII:E9PC7N0DID
DSSTox Substance ID:DTXSID801153092
Nikkaji Number:J2.120.976G
Wikidata:Q27087731
Pharos Ligand ID:HMC4B7AN53C2
ChEMBL ID:CHEMBL239226
Mol file:475085-57-5.mol

Synonyms:(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid;ACT-333679;MRE 269;MRE-269;MRE269

Suppliers and Price of (4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid

Supply Marketing:Edit

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

Usbiological
MRE-269
5mg
$ 340.00

TRC
MRE-269
10mg
$ 120.00

DC Chemicals
MRE-269 >98%
100 mg
$ 500.00

DC Chemicals
MRE-269 >98%
250 mg
$ 800.00

Crysdot
MRE-269 95+%
100mg
$ 385.00

Crysdot
MRE-269 95+%
50mg
$ 210.00

Crysdot
MRE-269 95+%
25mg
$ 170.00

ChemScene
MRE-269 99.46%
5mg
$ 60.00

ChemScene
MRE-269 99.46%
10mg
$ 110.00

ChemScene
MRE-269 99.46%
100mg
$ 450.00

Total 46 raw suppliers

Chemical Property of (4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid Edit

Chemical Property:

Boiling Point:602.1±55.0 °C(Predicted)
PKA:3.51±0.10(Predicted)
PSA：75.55000
Density:1.160
LogP:4.90680
Storage Temp.:Hygroscopic, -20°C Freezer, Under inert atmosphere
Solubility.:Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
XLogP3:4.5
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:6
Rotatable Bond Count:11
Exact Mass:419.22089180
Heavy Atom Count:31
Complexity:518

Purity/Quality:

HPLC>99%, max single impurity NMT 0.3% ^*data from raw suppliers

MRE-269 ^*data from reagent suppliers

Safty Information:

Pictogram(s):
Hazard Codes:

MSDS Files:: SDS file from LookChem

Useful:

Canonical SMILES:CC(C)N(CCCCOCC(=O)O)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
Description Prostacyclin (PGI2) is a potent vasorelaxant and inhibitor of platelet aggregation. It mediates its actions by binding to a specific G protein-coupled receptor, the IP receptor, on the surface of endothelial cells, arterial smooth muscle, and platelets. The IP receptor also participates in signal transduction of the pain response, cardioprotection, and inflammation. MRE-269 is the active form of the prodrug NS-304. It is a potent and selective agonist for the human IP receptor with a Ki value of 20 nM. In contrast to PGI2, which has a half-life of 30 seconds to a few minutes in vivo, plasma concentrations of MRE-269 remain near peak levels for more than eight hours in rats and dogs. Unlike the PGI2 analogues, beraprost and iloprost, MRE-269 lacks high affinity for the EP3 receptor. As a result, MRE-269 induces vasodilation equally in large and small pulmonary arteries, whereas vasodilation of small arteries by beraprost and iloprost is reduced via EP3-mediated vasoconstriction.
Uses MRE-269 an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269 is used for the treatment of pulmonary arterial hypertension. MRE-269 is an active metabolite of Selexipag (S253150).

Technology Process of (4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid

There total 16 articles about (4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 90.0%